281 related articles for article (PubMed ID: 478204)
21. [Anti-hyperlipidemic effect of iodine eggs: studies on the mechanism of its action].
Kaji K; Miyashita M; Seyama Y; Yamashita S
Nihon Yakurigaku Zasshi; 1984 May; 83(5):451-7. PubMed ID: 6469134
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
Tomita T; Takeshita R; Nagakura T; Hayashi E
Jpn J Pharmacol; 1973 Jun; 23(3):281-7. PubMed ID: 4541943
[No Abstract] [Full Text] [Related]
23. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
Seki K; Fukuda M; Isegawa J; Ohki M
Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
[No Abstract] [Full Text] [Related]
24. Reversal of clofibrate-induced cholesterol oversaturation of bile with chenodeoxycholic acid.
Bateson MC; Ross PE; Murison J; Bouchier IA
Br Med J; 1978 May; 1(6121):1171-3. PubMed ID: 638677
[TBL] [Abstract][Full Text] [Related]
25. The influence of dietary cholesterol on the lithogenesity of bile in rats treated with clofibrate (II).
Kawamoto T; Kajiyama G; Maruhashi A; Mizuno T; Yamada K; Fujiyama M; Miyoshi A
Hiroshima J Med Sci; 1981 Jun; 30(2):47-54. PubMed ID: 7298363
[No Abstract] [Full Text] [Related]
26. Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes.
Homcy CJ; Margolis S
Atherosclerosis; 1974; 19(3):381-91. PubMed ID: 4828566
[No Abstract] [Full Text] [Related]
27. Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man.
Pertsemlidis D; Panveliwalla D; Ahrens EH
Gastroenterology; 1974 Apr; 66(4):565-73. PubMed ID: 4821079
[TBL] [Abstract][Full Text] [Related]
28. Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.
Hall MJ; Nelson LM; Russell RI; Howard AN
Atherosclerosis; 1981 Jul; 39(4):511-6. PubMed ID: 6942844
[TBL] [Abstract][Full Text] [Related]
29. Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate.
Mazzella G; Bazzoli F; Villanova N; Simoni P; Festi D; Roda A; Aldini R; Roda E
Scand J Gastroenterol; 1990 Dec; 25(12):1227-34. PubMed ID: 2274744
[TBL] [Abstract][Full Text] [Related]
30. Effects of plasma cholesterol lowering agents on hepatobiliary lipid metabolism and cholesterol turnover in the rhesus monkey.
Redinger RN; Passi RB
Can J Physiol Pharmacol; 1979 Mar; 57(3):235-41. PubMed ID: 109175
[TBL] [Abstract][Full Text] [Related]
31. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
Grundy SM; Mok HY
J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
[TBL] [Abstract][Full Text] [Related]
32. Effects of clofibrate on some microsomal hydroxylations involved in the formation and metabolism of bile acids in rat liver.
Angelin BO; Björkhem I; Einarsson K
Biochem J; 1976 May; 156(2):445-8. PubMed ID: 942417
[TBL] [Abstract][Full Text] [Related]
33. Experimental studies on pharmacology, metabolism and toxicology with tiadenol-disulfoxide. Dissociation of lipid lowering effects and the induction of peroxisomal and microsomal drug-metabolizing enzymes.
Maffei Facino R; Carini M; Tofanetti O; Casciarri I; Longoni E
Arzneimittelforschung; 1987 Jun; 37(6):682-91. PubMed ID: 3663266
[TBL] [Abstract][Full Text] [Related]
34. A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
Xie YD; Chen ZZ; Shao LH; Wang QT; Li N; Lu WF; Xu YH; Gao YQ; Guo LY; Liu HL; Li YP; Yang GD; Bian XL
Bioorg Med Chem Lett; 2018 Oct; 28(18):3119-3122. PubMed ID: 30119959
[TBL] [Abstract][Full Text] [Related]
35. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.
Leiss O; von Bergmann K; Gnasso A; Augustin J
Metabolism; 1985 Jan; 34(1):74-82. PubMed ID: 3855325
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
[TBL] [Abstract][Full Text] [Related]
37. Carboxylic metabolites of tiadenol as "proximate" inducers of hepatic peroxisomal beta-oxidation activity.
Maffei Facino R; Carini M; Tofanetti O
Pharmacol Res Commun; 1988 Apr; 20(4):265-76. PubMed ID: 3387457
[TBL] [Abstract][Full Text] [Related]
38. 780 SE: a new type of hypolipemic agent. Comparative assays in rats.
Duhault J; Boulanger M; Beregi L; Sicot N; Bouvier F
Atherosclerosis; 1976; 23(1):63-72. PubMed ID: 1078395
[TBL] [Abstract][Full Text] [Related]
39. Regulation of biliary cholesterol secretion in the rat. Role of hepatic cholesterol esterification.
Nervi F; Bronfman M; Allalón W; Depiereux E; Del Pozo R
J Clin Invest; 1984 Dec; 74(6):2226-37. PubMed ID: 6511924
[TBL] [Abstract][Full Text] [Related]
40. The effect of etofibrate on cholesterol and bile acid metabolism in the hamster.
De Fabiani E; Crestani M; Malavasi B; Del Puppo M; Farina F; Armocida C; Bellentani S; Quack G; Bosisio E
Pharmacol Res; 1989; 21(5):567-76. PubMed ID: 2594613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
